New Notices
- New Notice of Intent to Revise: <795> Pharmaceutical Compounding—Nonsterile Preparations (posted 01–Sep–2021)
- New Notice of Intent to Revise: <797> Pharmaceutical Compounding— Sterile Preparations (posted 01–Sep–2021)
- New Notice of Intent to Revise: Bifidobacterium bifidium (posted 27–Aug–2021)
- New Notice of Intent to Revise: Bifidobacterium longum subsp. longum (posted 27–Aug–2021)
- New Notice of Intent to Revise: Lactobacillus reuteri (posted 27–Aug–2021)
- New Notice of Intent to Revise: Lactobacillus rhamnosus (posted 27–Aug–2021)
- New Notice of Intent to Revise: Magnesium Family of Monographs (posted 27–Aug–2021)
- New General Announcement: USP Virtual Roundtable on Reporting Thresholds in Monographs (held on June 29, 2021) (posted 27–Aug–2021)
- New Notice of Intent to Revise: Dextran 40 (posted 30–Jul–2021)
- New Notice of Intent to Revise: Dextran 70 (posted 30–Jul–2021)
- New Notice of Intent to Revise: Mesalamine Delayed-Release Tablets (posted 30–Jul–2021)
- Notice of Intent to Revise: Monographs with Postponed Content (posted 30–Jul–2021)
- New Notice of Intent to Revise: Rotigotine (posted 30–Jul–2021)
- New Notice of Intent to Revise: Technetium Tc 99m Monographs: Removal of Biological Tests (posted 30–Jul–2021)
- New Notice of Intent to Revise: Inhalation Drug Product Monographs: Removal of Performance Tests (posted 25–Jun–2021) | En español
- Updated General Announcement: New Inhalation Product Monographs: Proposed Approach for Performance Tests Employing Non-Standard Apparatus (posted 25–Jun–2021)
- New General Announcement: Bacterial Endotoxin Test (BET): A USP Comparability Study of Recombinant Reagents (Recombinant Factor C and Recombinant Cascade) to Lysate Reagents (LAL) (posted 25–Jun–2021)
- Update Notice of Intent to Revise: Sucrose (posted 18–Jun–2021)
- New General Announcement: Bacterial Endotoxins Test (BET): USP Requests Additional Data for the Comparability of Recombinant Reagents to Compendial Reagents (posted 11–Jun–2021)
- List of Monographs Appearing in Redesigned Format as of USP–NF 2021, Issue 3 (posted 01–Jun–2021)
- New Pending Notice of Intent to Revise: Lacosamide (posted 28–May–2021)